Claims

1. A compound of formula (I):



Formula (I)

including any tautomer thereof; or an isomer thereof in which the C26, 27 C=C bond shown as *trans* is *cis*; and including a methanol adduct thereof in which a ketal is formed by the combination of the C-53 keto (if present) and the C-15 hydroxyl group and methanol;

or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 is solid crystalline form.
3. A compound according to claim 2 in the form of its Form I crystalline polymorph.
4. A compound according to any one of claims 1 to 3 for use as a pharmaceutical.
5. A compound according to any one of claims 1 to 3 for use as a pharmaceutical for the treatment of viral infections such as HCV or HIV infection or as an immunosuppressant or an anti-inflammatory agent.
6. A pharmaceutical composition comprising a compound according to any one of claims 1 to 3 together with a pharmaceutically acceptable diluent or carrier.
7. A pharmaceutical composition comprising a compound according to any one of claims 1 to 3 together with a pharmaceutically acceptable diluent or carrier further comprising a second or subsequent active ingredient.
8. ~~A method of treatment of viral infections such as HCV or HIV infection or for use as an immunosuppressant or an anti-inflammatory agentwhich comprises administering to a subject a therapeutically effective amount of a compound according to any one of claims 1 to 3.~~
9. A process for preparing a compound according to claim 1 which comprises reacting a compound of formula (V)



Formula (V)

wherein each R_{11} is independently C_{1-4} alkyl or benzyl;

with an aldehydic macrocycle (compound of formula VI):



Formula (VI)

~~109~~. A compound of formula (VI):



Formula (VI)

~~1110~~. A process for the preparation of a compound of formula (I) in the form of its Form I crystalline polymorph according to claim 3 comprising the step of crystallising a compound of formula (I) from methyl isobutyl ketone.